Debio 025 - Debiopharm

Home » Media » Press Releases

Debio 025

Date	Article Title
09 Feb 2010	Debiopharm Group™ grants an exclusive licence for the development, manufacture and commercialisation of Debio 025 - A potent, first-in-class antiviral agent for the treatment of Hepatitis C -
30 Apr 2009	Clinical Update – Debio 025 in Hepatitis C - Debiopharm starts phase IIb study after record time patient randomisation
28 Apr 2009	Clinical Update – Debio 025 in Hepatitis C - Debiopharm presents promising phase IIa results showing potent antiviral activity
23 Jan 2009	Clinical Update – Debio 025 in Hepatitis C - Debiopharm starts phase IIb triple therapy study, a promising therapeutic avenue
28 Apr 2008	Clinical Update – Debio 025 in Hepatitis C - Presentation of Phase IIa Efficacy Results
18 Apr 2007	Clinical update - Debio 025 cyclophilin inhibitor for the treatment of HCV - A unique viral kinetics
31 Oct 2006	Debiopharm presents new data confirming anti-HCV activity of cyclophilin inhibitor for Debio-025
09 Feb 2006	Debiopharm S.A. presented results of a double-blind placebo-controlled study on first-in-class Debio-025 in HIV-1-infected subjects
06 Oct 2004	New Data presented on Debiopharm´s Debio-025 at the 11th International Symposium on Hepatits C virus and related viruses

Latest News

09 November 2011 Augurix Diagnostics receives the 2011 ‘Debiopharm /Valais Award’ For its point-of-care diagnostic test for the early detection of Celiac disease

05 October 2011 The Japanese Cancer Association and Debiopharm Group™ present Doctors Arakawa and Kurokawa with the 2011 ‘JCA-Mauvernay Award’for their innovative and outstanding research in the field of cancer

08 September 2011 Debiopharm Group™ presents the ‘Debiopharm Group™ Life Sciences Award 2011’ and two ‘Junior Debiopharm Group™ Awards 2011’ at the ISREC 2011 Life Sciences Symposium

Debiopharm on

© 2012 Debiopharm Group